737751-54-1Relevant articles and documents
Coordination Chemistry of Borane in Solution: Application to a STING Agonist
Lemaire, Sébastien,Zhdanko, Alexander,van der Worp, Boris A.
, (2022/04/09)
Equilibrium constants were determined for ligand exchange reactions of borane complexes with various oxygen, sulfur, nitrogen, and phosphorus nucleophiles in solution, and a binding affinity scale was built spanning a range of 12 orders of magnitude. While the Keq are minimally dependent on the solvent, the rate of ligand exchange varies significantly. The fastest and slowest rates were observed in THF and CDCl3, respectively. Moreover, the ligand exchange rate differs in a very broad range depending on stability of the starting complex. Binding of BH3 was found to be much more sensitive to steric factors than protonation. Comparing nitrogen bases having equal steric properties, a linear correlation of BH3 binding affinity vs. Br?nsted acidity was found. This correlation can be used to quickly estimate the BH3 binding affinity of a substrate if pKa is known. Kinetic studies suggest the ligand exchange to occur as a bimolecular SN2 reaction unless other nucleophilic species were present in the reaction mixture.
Phosphine Oxides (-POMe2) for Medicinal Chemistry: Synthesis, Properties, and Applications
Stambirskyi, Maksym V.,Kostiuk, Tetiana,Sirobaba, Serhii I.,Rudnichenko, Alexander,Titikaiev, Dmytro L.,Dmytriv, Yurii V.,Kuznietsova, Halyna,Pishel, Iryna,Borysko, Petro,Mykhailiuk, Pavel K.
, p. 12783 - 12801 (2021/09/18)
A general practical approach to hetero(aromatic) and aliphatic P(O)Me2-substituted derivatives is elaborated. The key synthetic step was a [Pd]-mediated C-P coupling of (hetero)aryl bromides/iodides with HP(O)Me2. The P(O)Me2 substituent was shown to dramatically increase solubility and decrease lipophilicity of organic compounds. This tactic was used to improve the solubility of the antihypertensive drug prazosin without affecting its biological profile.
KINASE INHIBITORS
-
Paragraph 0562; 0563, (2016/12/12)
There are provided compounds of formula I. wherein R1 to R5, X1, X2, Ar, L, A, A1, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
KINASE INHIBITORS
-
Paragraph 0458 - 0460, (2015/08/04)
There are provided compounds of formula (I), wherein R1 to R5, X1, X2, Ar, L, A, A1, E and G have meanings given in the description, which compounds have anti-inflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
